NCT05245006 - PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Prostate CancerMetastatic Castration-resistant Prostate Cancer

Interventions

DRUG

89Zr-DFO-YS5

3 mCi will be administered intravenously

BIOLOGICAL

YS5 antibody

20 or 50 mg administered intravenously

PROCEDURE

Positron Emission Tomography (PET)/Computerized tomography (CT)

Imaging which combines a CT scan and a PET scan

PROCEDURE

Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)

Imaging which combines an MRI scan and a PET scan

Trial Locations (1)

RECRUITING

University of California, San Francisco, San Francisco